MedTrace Logo

Investigation of Three Biomarkers for the Detection of Prostate Cancer

NCT06554587 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 137

Last updated 2025-01-17

No results posted yet for this study

Summary

GlycoScore Dx Limited, a diagnostics company based in the United Kingdom have identified three glycoproteins, that showed promise as biomarkers of prostate cancer in initial validation studies. The purpose of this study is to further evaluate the sensitivity and specificity of the GlycoScore biomarkers for the detection of clinically significant prostate cancer. Sensitivity and specificity will be determined for each marker, combinations of the three markers and combinations of the GlycoScore biomarkers with PSA (prostate specific antigen). The results from this study will be used to identify the most suitable biomarker/biomarkers for use in developing a GlycoScore test.

This is a prospective, non-interventional study using venous blood samples taken from patients with suspected prostate cancer or on active surveillance, attending the hospital Urology department for a transperineal biopsy.

Conditions

  • Cancer of Prostate

Interventions

DIAGNOSTIC_TEST

Laboratory Biomarker Analysis: Enzyme-linked immunosorbent assay (ELISA)

Measurement of the plasma concentration of ST6GAL1, GCNT1 and GALNT7 biomarkers in patients suspected of having prostate cancer or on active surveillance

Sponsors & Collaborators

  • GlycoscoreDx Ltd

    collaborator UNKNOWN

  • Medtechtomarket Consulting Ltd

    lead INDUSTRY

Principal Investigators

  • Henry P Lazarowicz, FRCS(Urol) · Liverpool University Hospitals NHS Foundation Trust

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-07
Primary Completion
2026-01-07
Completion
2026-03-07

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06554587 on ClinicalTrials.gov